Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Moving up

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Jan 05, 2022 10:51am

336 Views

Post# 34285097

RE:Moving up

Duster340 wrote: the stock wants to run, just waiting for the catalyst, like an update from management and some insider buying would be nice. that would get us back above $1

Yes - demand will drive the price.
We just don't know how long it will take for investors to get excited once again.
Should be a natural progression as we head to P2 ... especially with a few other catalysts throughout the year.

Big question is ... can they deliver in a timely manner - catalysts and P2 start ? Time will tell.

<< Previous

Bullboard Posts

Next >>

From now on, dynaCERT instead of Bitcoin or NVIDIA?